ProfileGDS5678 / 1445375_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 60% 59% 64% 59% 58% 59% 59% 59% 60% 69% 60% 59% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6060659
GSM967853U87-EV human glioblastoma xenograft - Control 23.5822260
GSM967854U87-EV human glioblastoma xenograft - Control 33.5533259
GSM967855U87-EV human glioblastoma xenograft - Control 43.8596164
GSM967856U87-EV human glioblastoma xenograft - Control 53.5116759
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5759758
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6110459
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5437159
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5465859
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5525760
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2534469
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5531560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5752559
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0732167